The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success-Reference-Cited by-同舟云学术

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

Published:2020-10-27 Issue:12 Volume:29 Page:1365-1375
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Drenth Joost P.H.¹,Schattenberg Jörn M.²³^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands

2. Department of Medicine, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany

3. Metabolic Liver Research Program, University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1839888

Reference60 articles.

1. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

2. Shetty A, Syn WK. Health and economic burden of nonalcoholic fatty liver disease in the United States and its impact on veterans. Federal practitioner: for the health care professionals of the VA, DoD, and PHS. 2019;36(1):14–19.

3. [cited 2020 Oct 23]. Available from: https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market

4. JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study

5. Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation;Redox Biology;2024-10

2. News in gastroenterology, hepatology and digestive endoscopy;Vnitřní lékařství;2024-09-04

3. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression;Journal of Hepatology;2024-09

4. Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma;Journal of Hepatology;2024-09

5. Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions;Life Sciences;2024-08